General Announcement::Glenmark launches Nitric Oxide Nasal Spray (FabiSpray) in India

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-Feb-2022 13:28:28
Status
New
Announcement Sub Title
Glenmark launches Nitric Oxide Nasal Spray (FabiSpray) in India
Announcement Reference
SG220209OTHRKSDX
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/02/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark launches Nitric Oxide Nasal Spray (FabiSpray) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize.

Attachments

SGX_PR_09022022.pdf
Total size =990K